Regeneron Pharmaceuticals has been granted a patent for compositions containing anti-VEGF proteins. The patent includes a claim for a culture media composition with chemically defined media and oxidized aflibercept. GlobalData’s report on Regeneron Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Regeneron Pharmaceuticals, Transgenic murine models was a key innovation area identified from patents. Regeneron Pharmaceuticals's grant share as of May 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
Culture media composition with anti-vegf proteins
A recently granted patent (Publication Number: US12012444B2) discloses a culture media composition that includes chemically defined media (CDM) and aflibercept. The composition contains between 0.02% to 1% oxidized aflibercept, with the oxidation occurring at specific amino acid residues such as tryptophan, histidine, or a combination thereof. The patent specifies different levels of oxidized aflibercept at various amino acid residues, ranging from 0.02% to 0.19%, highlighting the importance of these specific oxidized forms in the culture media composition.
Furthermore, the patent details the relative abundance of oxidized residues like His19, His86, His95, His110, His145, His203, His209, Trp58, and Trp138 in the aflibercept component of the culture media composition. These specific oxidized residues play a crucial role in the overall composition, with relative abundances ranging from at least 0.02% to 0.19%. By outlining these precise levels and locations of oxidation within the aflibercept molecule, the patent provides valuable insights for researchers and developers working in the field of culture media compositions for various applications.
To know more about GlobalData’s detailed insights on Regeneron Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
